Erasca Inc.

Advice for CEOs and CFOs as they navigate the year ahead

Gainers, decliners among companies presenting at this week’s J.P. Morgan Healthcare Conference

Plus: Erasca strikes two deals for RAS-targeting therapies, AZ plans new ADC manufacturing site, and more 

Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback

Plus: Lucera named CFO at Editas, and updates from Erasca, Sangamo, AlloVir and more

Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more

Plus: Erasca adds pan-RAF inhibitor from Novartis, and updates from UCB, Ambrx, Pharvaris and more 

Plus OrbiMed alum Khuong joins Catalio Capital, Warma named CEO of Genexine and more

Erasca, Imago posted single-digit gains, while TScan shed nearly a third of its value

With backing from high-profile crossover investors, four-year-old company taking wholly-owned HIF2A program into clinic